比美吉珠单抗治疗中重度斑块状银屑病3年安全性汇总分析
该分析汇总三项III期试验及其开放标签扩展研究,评估比美吉珠单抗(BKZ)治疗中重度斑块状银屑病长达3年的安全性。1495例患者累计暴露3876.4患者年,总体治疗中出现的不良事件(TEAE)暴露调整发生率(EAIR)为175.5/100患者年,随暴露延长而下降;口腔念珠菌病99.3%为轻中度,无严重事件。未发现新的安全性信号。
要点
- BKZ长期暴露未发现新的安全性信号,总体TEAE发生率随治疗时间延长而下降。
- 口腔念珠菌病常见但99.3%为轻中度,无严重事件,极少导致停药。
- 严重感染、炎症性肠病及肝酶显著升高的EAIR均较低。
核心结论
- 在中重度斑块状银屑病患者中,BKZ治疗长达3年未观察到新的安全性信号。
- 绝大多数口腔念珠菌病事件为轻中度,与此前报告一致。
研究设计与样本
- 汇总三项III期随机试验(BE VIVID、BE READY、BE SURE)及其正在进行的开放标签扩展研究(BE BRIGHT)长达3年的安全性数据。
- 共1495例患者至少接受一剂BKZ,总BKZ暴露为3876.4患者年。
- 采用暴露调整发生率(EAIR)/100患者年报告治疗中出现的不良事件(TEAE)。
主要发现
- 总体TEAE的EAIR为175.5/100患者年,且随BKZ暴露时间延长而下降。
- 最常见TEAE为鼻咽炎、口腔念珠菌病和上呼吸道感染,EAIR分别为15.0/100患者年、10.1/100患者年和6.5/100患者年。
- 口腔念珠菌病事件中99.3%为轻中度,无严重事件,极少导致停药。
- 其他关注TEAE的EAIR较低:严重感染1.2/100患者年,裁定炎症性肠病0.2/100患者年,天冬氨酸氨基转移酶或丙氨酸氨基转移酶升高(>5倍正常上限)0.6/100患者年。
临床怎么用
- 长期使用BKZ治疗中重度斑块状银屑病时,口腔念珠菌病较常见但多为轻中度,可据此进行监测和管理。
- 严重感染、炎症性肠病及肝酶显著升高的发生率较低,长期治疗中仍需保持关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with psoriasis require long-term management; therefore, understanding the long-term safety of new treatments, such as bimekizumab (BKZ), is crucial. OBJECTIVES: To evaluate BKZ's 3-year safety profile in patients with moderate-to-severe plaque psoriasis. METHODS: Three years of safety data were pooled from three phase III trials (BE VIVID, BE READY and BE SURE) and their ongoing open-label extension (BE BRIGHT). Treatment-emergent adverse events (TEAEs) are reported using exposure-adjusted incidence rates (EAIRs) per 100 patient-years (PY). RESULTS: In total, 1495 patients received at least one BKZ dose; total BKZ exposure was 3876.4 PY. The overall EAIR of TEAEs was 175.5/100 PY and decreased with longer exposure to BKZ. The most commonly reported TEAEs were nasopharyngitis, oral candidiasis and upper respiratory tract infection (EAIRs of 15.0/100 PY, 10.1/100 PY and 6.5/100 PY, respectively); 99.3% of oral candidiasis events were mild or moderate in severity, none were serious and few led to discontinuation. EAIRs of other TEAEs of interest were low, including serious infections (1.2/100 PY), adjudicated inflammatory bowel disease (0.2/100 PY) and laboratory elevations in aspartate aminotransferase or alanine aminotransferase (> 5 × upper limit of normal: 0.6/100 PY). CONCLUSIONS: In these analyses pooled across 3 years, no new safety signals were observed with longer exposure to BKZ. The vast majority of oral candidiasis events were mild or moderate in severity, as reported previously.
引用
- Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024. PMID: 37950894. doi:10.1093/bjd/ljad429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。